Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 20 di 56
Titolo Tipologia Data di pubblicazione Autori File
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 01 - Articolo su rivista 2024 Ilari, AliceSherif, NoorhanGrassilli, EmanuelaRamazzotti, DanieleCordani, NicolettaCazzaniga, GiorgioDi Bella, CamilloLavitrano, MarialuisaCazzaniga, Marina ElenaCerrito, Maria Grazia +
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 02 - Intervento a convegno 2023 Gotuzzo, ICazzaniga, MDe Bernardi, ECicchiello, FCordani, NCerrito, MTurolla, ELandoni, CCrivellaro, CVirdone, LMonaco, LGuerra, L +
"Ironing out" fasting-induced persister cancer cells to render chemotherapy effective: is this the solution? 01 - Articolo su rivista 2023 Grassilli, EmanuelaCerrito, Maria Grazia
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 02 - Intervento a convegno 2023 Nicoletta CordaniLuca MologniRocco PiazzaCamillo Di BellaMaria Grazia CerritoMatteo VillaGuido CavalettiMarialuisa LavitranoMarina Elena Cazzaniga +
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 01 - Articolo su rivista 2023 Nicoletta CordaniLuca MologniRocco PiazzaPietro TettamantiMario MauriMatteo VillaFederica MalighettiCamillo Di BellaMaria Grazia CerritoGuido CavalettiMarialuisa LavitranoMarina Elena Cazzaniga +
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 01 - Articolo su rivista 2023 Nicoletta CordaniGiuseppe PagliaRamona MeantiMaria Grazia CerritoChiara VillaMario MauriLuca MologniAntonio TorselloMarina Elena Cazzaniga +
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story 01 - Articolo su rivista 2022 Cicchiello F.Cordani N.Cerrito M. G.Cazzaniga M. E. +
BTK, the new kid on the (oncology) block? 01 - Articolo su rivista 2022 Grassilli, EmanuelaCerrito, Maria GraziaLavitrano, Marialuisa
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows 01 - Articolo su rivista 2022 Marina Elena CazzanigaNicoletta CordaniMaria Grazia Cerrito +
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation 01 - Articolo su rivista 2022 Scagliotti A.Capizzi L.Cazzaniga M. E.Ilari A.Cordani N.Albini A.Lavitrano M.Grassilli E.Cerrito M. G. +
An Olive Oil Mill Wastewater Extract Improves Chemotherapeutic Activity Against Breast Cancer Cells While Protecting From Cardiotoxicity 01 - Articolo su rivista 2022 Cerrito M. G.Pelosi G.Albini A. +
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study 01 - Articolo su rivista 2022 Cazzaniga M. E.Baroni S.Cicchiello F.Cordani N.Cerrito M. G. +
Emerging actionable targets to treat therapy-resistant colorectal cancers 01 - Articolo su rivista 2022 Grassilli E.Cerrito M. G.
Metronomic chemotherapy 01 - Articolo su rivista 2021 Cazzaniga M. E.Cordani N.Cerrito M. G. +
p65BTK Is a Novel Biomarker and Therapeutic Target in Solid Tumors 01 - Articolo su rivista 2021 Grassilli E.Cerrito M. G.Bonomo S.Giovannoni R.Conconi D.Lavitrano M.
Identifying novel actionable targets in colon cancer 01 - Articolo su rivista 2021 Cerrito M. G.Grassilli E.
Does additional coronary artery bypass grafting to aortic valve replacement in elderly patients affect the early and long-term outcome? 01 - Articolo su rivista 2020 Formica, FCerrito, MG +
BTK inhibitors synergise with 5-FU to treat drug-resistant TP53-null colon cancers 01 - Articolo su rivista 2020 Lavitrano, MarialuisaIanzano, LeonardaBonomo, SaraCerrito, Maria GraziaGiovannoni, RobertoRomano, GabrieleNOLI, BARBARALeone, Biagio EugenioGrassilli, Emanuela +
Sperm-Mediated Genetic Modifications 03 - Contributo in libro 2020 Lavitrano, MFarina, LCerrito, MGGiovannoni, R
The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation 01 - Articolo su rivista 2020 Scagliotti A.Grassilli E.Cazzaniga M. E.Lavitrano M.Cerrito M. G. +
Mostrati risultati da 1 a 20 di 56
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile